Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2016-06-30
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spinal Plasticity to Enhance Motor Retraining After Stroke
NCT03645122
Mechanisms of Arm Recovery in Stroke Patients With Hand Paralysis
NCT03067818
Brain Stimulation and Tailored Interventions to Promote Recovery in Stroke Survivors
NCT02915185
Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis
NCT00170716
Perceptual-motor Interaction to Improve Bimanual Coordination After Stroke
NCT03755076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Overall objectives of the proposal are:
1. To test the effectiveness of personalized training programs to increase the range of regulation of STs in the elbow during reaching.
2. To determine the effects of repetitive tDCS aimed at inhibiting excessive/exciting diminished cortical activity.
3. To determine the feasibility of implementing personalized training programs in high and low-to-middle income countries.
Sixty patients with sub-acute (3 wks-6 mos) stroke will be recruited in this multi-site international trial taking place in Canada, Israel and India. Participants will have spasticity in the elbow flexors and/or extensors, with some active elbow control. Each site will recruit and randomize patients into one of 3 treatment groups. Group 1 will receive tDCS and practice personalized arm motor training. Group 2 will also receive tDCS with non-specific practice. Group 3 will receive Sham-tDCS and personalized practice. Training will consist of the application of tDCS in the first 30 minutes of a 50-minute arm reaching practice session,, 5 days per week for 2 weeks. Primary outcome measures (Pre, Post, Follow-up) are elbow flexor and extensor STs and related spasticity/active control zones. Secondary measures are clinical measures of UL motor activity. By accounting for the spatial structure of motor deficits, our research will benefit both researchers and clinicians by advancing our understanding of the mechanisms underlying unimpaired/impaired motor control and recovery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tDCS + personalized practice
Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
tDCS
Application of 1.5 mA tDCS for 30 minutes
personalized practice
arm exercise consisting of whole arm movement within a restricted elbow range of motion
tDCS + non-personalized practice
Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
tDCS
Application of 1.5 mA tDCS for 30 minutes
non-personalized practice
arm exercise consisting of unrestricted whole arm movement
sham tDCS + personalized practice
Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
sham tDCS
Application of sham tDCS for 30 minutes
personalized practice
arm exercise consisting of whole arm movement within a restricted elbow range of motion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tDCS
Application of 1.5 mA tDCS for 30 minutes
sham tDCS
Application of sham tDCS for 30 minutes
personalized practice
arm exercise consisting of whole arm movement within a restricted elbow range of motion
non-personalized practice
arm exercise consisting of unrestricted whole arm movement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. sub-acute stage of stroke (3 wk to 6 mo post-stroke);
3. arm paresis (Chedoke-McMaster Arm Scale of 2-6 /7; Gowland et al. 1993) but able to perform voluntary elbow flexion/extension of at least 30° per direction;
4. elbow flexor and/or extensor spasticity (\> 1+/4 on Modified Ashworth Scale; Ashworth 1964; Bohannon and Smith 1987);
5. able to provide informed consent.
Exclusion Criteria
2. major cognitive deficits (a score \<20 on the Montreal Cognitive Assessment, Nasreddine et al. 2005);
3. history of psychiatric disorders, alcohol or drug abuse, skin sensitivity, seizures, migraines, metal in cranium and other implants (cochlear, cardiac);
4. taking medications (e.g. epileptic and psychoactive drugs) that could affect brain activity (Poreisz 2007).
25 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel Aviv University
OTHER
Manipal University
OTHER
McGill University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mindy F. Levin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mindy F Levin, PhD
Role: PRINCIPAL_INVESTIGATOR
McGill University
Dario G Liebermann, PhD
Role: PRINCIPAL_INVESTIGATOR
Tel Aviv University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CRIR
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
ASHWORTH B. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. Practitioner. 1964 Apr;192:540-2. No abstract available.
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7. doi: 10.1093/ptj/67.2.206.
Gowland C, Stratford P, Ward M, Moreland J, Torresin W, Van Hullenaar S, Sanford J, Barreca S, Vanspall B, Plews N. Measuring physical impairment and disability with the Chedoke-McMaster Stroke Assessment. Stroke. 1993 Jan;24(1):58-63. doi: 10.1161/01.str.24.1.58.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.
Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull. 2007 May 30;72(4-6):208-14. doi: 10.1016/j.brainresbull.2007.01.004. Epub 2007 Jan 24.
Levin MF, Berman S, Weiss N, Parmet Y, Banina MC, Frenkel-Toledo S, Soroker N, Solomon JM, Liebermann DG. ENHANCE proof-of-concept three-arm randomized trial: effects of reaching training of the hemiparetic upper limb restricted to the spasticity-free elbow range. Sci Rep. 2023 Dec 22;13(1):22934. doi: 10.1038/s41598-023-49974-6.
Levin MF, Banina MC, Frenkel-Toledo S, Berman S, Soroker N, Solomon JM, Liebermann DG. Personalized upper limb training combined with anodal-tDCS for sensorimotor recovery in spastic hemiparesis: study protocol for a randomized controlled trial. Trials. 2018 Jan 4;19(1):7. doi: 10.1186/s13063-017-2377-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
108186-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.